Daxor Corporation -AMEX: DXR- Announces Third Quarter Earnings 2003.

Business Editors

NEW YORK--(BUSINESS WIRE)--Nov. 13, 2003

Daxor Corporation (AMEX: DXR)

                      Three Months Ended         Nine Months Ended
                         September 30               September 30

                         2003        2002        2003         2002

Total Revenues     $   904,183  $   794,270  $ 2,413,467  $ 2,209,196

Net Income (loss)  $  (180,041) $   105,009  $  (702,280) $   215,674

Weighted Average
 Number of Shares
 Outstanding         4,645,826    4,663,909    4,649,347    4,664,576

Equivalent Share   $     (0.04) $      0.02  $     (0.15) $      0.05

Daxor Corporation, (AMEX: DXR), a leading medical instrumentation and biotechnology company, today announced operating revenues, excluding dividend income, increased by 51% in the third quarter of 2003. This was related to an increase in marketing efforts. Sales of Blood Volume Analyzers to a hospital client may require a 6 to 12 month cycle from initial contact to placement of an instrument. The time frame may be shorter for a physician's office or diagnostic center. A Blood Volume Analyzer can be obtained through a lease, direct sale or loaner program. It is anticipated that the main income will ultimately come from the associated Volumex kits. The Company has increased research expenses for additional features to the BVA-100.

Daxor manufactures and markets the BVA-100 a semi-automated Blood Volume Analyzer. The BVA-100 is used in conjunction with a single use diagnostic kit. It is the first FDA approved instrument to provide rapid direct measurement of a patient's blood volume. The BVA-100 enables physicians to have access to technology which allows them to obtain blood volume measurements rapidly and with a high degree of precision.

Additional information about the BVA-100 and other medical studies can be found on Daxor's website at www.daxor.com.